Verification of Novel Treatment Strategy with Eribulin Based on the Tumor Microenvironment for Breast Cancer

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K18046
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55010:General surgery and pediatric surgery-related
• Research Institution: Osaka Metropolitan University (2022-2023); Osaka City University (2020-2021); Osaka City General Hospital (2019)
• Principal Investigator: Goto Wataru 大阪公立大学, 大学院医学研究科, 病院講師 (20824668)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: 乳癌 / エリブリン / 免疫微小環境

Outline of Final Research Achievements

Eribulin-resistant breast cancer cell lines were generated, and the immune microenvironment-related markers and immune checkpoints were altered compared to the parental lines to analyze the resistance mechanism. In addition, by modulating the changes in the immune microenvironment that iron chelators cause in breast cancer with eribulin, we demonstrated the advantages of combination therapy in terms of increased tumor shrinkage and improvement of the immune microenvironment. In addition, they generated hormone receptor-positive strains resistant to endocrine therapy, and showed that treatment with eribulin may release endocrine therapy resistance in these strains.
All three studies were published and accepted for publication.

Free Research Field

乳癌

Academic Significance and Societal Importance of the Research Achievements

本研究のテーマである“エリブリンにおける腫瘍微小環境制御による新たな乳癌治療戦略”について腫瘍低酸素やEMT，内分泌感受性，腫瘍免疫，代謝競合と様々な側面から探究をすすめてきたが、実臨床への応用可能な新たな治療戦略の構築につながる研究成果を示すことができた。
今後の乳癌治療の発展に寄与し得るという、学術的かつ社会的にも意義の大きい研究成果であった。